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LETTER TO THE EDITOR
Serum Levels of Interleukin 10 (IL-10) in Patients 
with Type 2 Diabetes 
 
 
Dear Editor, 
The frequency of diabetes mellitus is increasing and it is 
expected that this disorder will affect 300 million people in 
2025.
1 It has been suggested that diabetes is an immune 
dependent disease in which the pattern of cytokine expres-
sion is changed.
2 As an example, in type 2 diabetes, the 
monocytes of peripheral blood produce more inflammatory 
cytokines than those from normal patients.
2 The association 
of IL-10 in immunological disorders such as multiple scle-
rosis,
3,4 nephrotic syndrome
5, 6 and type-1 diabetes
7,8 is well 
established. The key role of IL-10 is to work as the main 
inhibitory cytokine against the action of inflammatory cy-
tokines such as IL-12. Based on evidence suggesting that 
immune responses may be important in inducing type 2 
diabetes,
9 this study was designed to evaluate serum levels 
of IL-10 in type 2 diabetes. Peripheral blood samples were 
collected from 131 type 2 diabetic patients and 120 healthy 
controls. The patient and control groups were matched for 
sex and age. IL-10 serum level was measured using ELISA 
kit (eBioscience, Spain) in both groups. The differences in 
variables were analyzed by student t tests. Results of our 
study showed that the mean IL-10 serum level was 
9.53±2.27 and 16.11±2.27 pg/ml in type 2 diabetic patients 
and control groups, respectively. Statistical analysis 
showed that the difference was significant (p<0.005). Our 
findings indicated a significant difference between IL-10 
serum levels in type 2 diabetic patients compared to healthy 
controls. Other researchers also showed same results such as 
Eric VE et al., 2002 who indicated that the serum levels of IL-
10 decreased in type 2 diabetic patients compared to con-
trols.
10 Based on this fact, it may be concluded that low serum 
levels of IL-10 can be considered as a risk factor of type 2 
diabetes. 
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